5 results on '"Canaani, Jonathan"'
Search Results
2. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Nagler, Arnon, Labopin, Myriam, Houhou, Mohamed, Aljurf, Mahmoud, Mousavi, Ashrafsadat, Hamladji, Rose-Marie, Al Zahrani, Mohsen, Bondarenko, Sergey, Arat, Mutlu, Angelucci, Emanuele, Koc, Yener, Gülbas, Zafer, Sica, Simona, Bourhis, Jean Henri, Canaani, Jonathan, Brissot, Eolia, Giebel, Sebastian, and Mohty, Mohamad
- Published
- 2021
- Full Text
- View/download PDF
3. Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
- Author
-
Canaani, Jonathan, Frisch, Avraham, Pollyea, Daniel A., Schwartz, Marc, Aumann, Shlomzion, Ganzel, Chezi, Haran, Arnon, Even‐Zohar, Noa Gross, Shaulov, Adir, Vainstein, Vladimir, Moshe, Yakir, Ofran, Yishai, Wolach, Ofir, and Nachmias, Boaz
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *SALVAGE therapy , *BONE marrow , *ADULTS - Abstract
Objectives: Dysregulation of BCL‐2 family members has been reported in acute lymphocytic leukemia (ALL), with various BH3‐dependencies of the leukemic clone. We conducted a multicenter retrospective cohort of patients with relapsed/refractory B or T ALL, with ven‐chemotherapy or ven‐navitoclax combinations, to assess efficacy and safety. Methods: Seventeen patients were included in the analysis, median age was 32 years, with 6 B‐ALL and 11 T‐ALL patients. Nine patients received venetoclax combined with chemotherapy, and 13 patients received venetoclax in combination with navitoclax, vincristine and asparaginase, of which 5 were already exposed to venetoclax in previous lines. Results: ORR was 55% and 46% among the ven‐chemotherapy and the ven‐navitoclax‐chemotherapy, respectively. Most of the responders proceeded to an allogenic bone marrow transplant in both cohorts. The most common adverse effects of the ven‐navitoclax combination were infectious complications and hepatotoxicity. Conclusions: Our data demonstrated the possible efficacy of ven‐chemotherapy and ven‐navitoclax in r/r ALL with moderate toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Outcome of T‐cell–replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
- Author
-
Nagler, Arnon, Labopin, Myriam, Koc, Yener, Angelucci, Emanuele, Tischer, Johanna, Arat, Mutlu, Pioltelli, Pietro, Bernasconi, Paolo, Chiusolo, Patrizia, Diez‐Martin, J. L., Sanz, Jamie, Ciceri, Fabio, Peric, Zinaida, Giebel, Sebastian, Canaani, Jonathan, and Mohty, Mohamad
- Subjects
HEMATOPOIETIC stem cell transplantation ,STEM cell transplantation ,ADULTS ,LYMPHOBLASTIC leukemia ,ACUTE leukemia ,OVERALL survival - Abstract
BACKGROUND: The use of haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplantation cyclophosphamide prophylaxis is gaining traction in patients with acute lymphoblastic leukemia (ALL). METHODS: The Acute Leukemia Working Party/European Society for Blood and Marrow Transplantation registry was used to evaluate the outcomes of adult patients with ALL who underwent haplo‐HCT during 2011 through 2015 and compared them with the outcomes of those who underwent transplantation during 2016 through 2018. RESULTS: The analysis consisted of 195 patients, including 79 who underwent transplantation during 2011 through 2015 and 116 who underwent transplantation during 2016 through 2018. Overall, the 2‐year leukemia‐free survival and relapse incidence rates were 56.5% and 21%, respectively. The 100‐day incidence of grade 2 through 4 acute graft‐vs‐host disease (GVHD) was 34.5%. The rates of nonrelapse mortality (NRM) and overall survival (OS) were 22.5% and 64.7%, respectively. Patients who underwent transplantation during 2016 through 2018 experienced improved rates of leukemia‐free survival (64.9% vs 47.3%; P =.019) and OS (75.5% vs 53.5%; P =.006). Patients who underwent transplantation during 2016 through 2018 developed more grade 2 through 4 acute GVHD (42% vs 26.4%; P =.047). The incidence of relapse, GVHD‐free/relapse‐free survival, grade 3 and 4 acute GVHD, chronic GVHD, and extensive chronic GVHD did not differ significantly between groups. In multivariate analysis, more recently transplanted patients had a significantly reduced risk of NRM (hazard ratio, 0.44; 95% CI, 0.22‐0.89; P =.022) and improved OS (hazard ratio, 0.47; 95% CI, 0.26‐0.86; P =.014). A comparable analysis of patients who had acute myeloid leukemia during the same timeframes did not reveal any statistically significant differences in any outcomes. CONCLUSIONS: The outcome of adult patients with ALL who receive posttransplant cyclophosphamide has improved over time, with an impressive 2‐year OS of 75% and, most recently, an NRM rate of only 17%. In patients with acute lymphocytic leukemia who undergo haploidentical transplantation with posttransplantation cyclophosphamide prophylaxis, significant improvements in leukemia‐free survival and survival are observed in more recently transplanted patients. A nonrelapse mortality rate of 17% is reported in recently transplanted patients with acute lymphocytic leukemia who receive posttransplantation cyclophosphamide prophylaxis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation
- Author
-
Johanna Tischer, Myriam Labopin, Arnon Nagler, Yener Koc, Xiao-Jun Huang, Fabio Ciceri, William Arcese, Benedetto Bruno, Maria Teresa Van Lint, Bipin N. Savani, Jonathan Canaani, Mohamad Mohty, Didier Blaise, Zafer Gulbas, Service d’Hématologie [Institut Paoli Calmettes, Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Canaani, Jonathan, Savani, Bipin N, Labopin, Myriam, Huang, Xiao-Jun, Ciceri, Fabio, Arcese, William, Koc, Yener, Tischer, Johanna, Blaise, Didier, Gülbas, Zafer, Van Lint, Maria Teresa, Bruno, Benedetto, Mohty, Mohamad, and Nagler, Arnon
- Subjects
Adult ,Male ,medicine.medical_specialty ,haploidentical hematopoietic cell transplantation ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,Acute Disease ,Age Factors ,Aged ,Female ,Hematopoietic Stem Cell Transplantation ,Humans ,Leukemia ,Middle Aged ,Registries ,Retrospective Studies ,Survival Analysis ,Transplantation, Haploidentical ,Treatment Outcome ,Unrelated Donors ,acute lymphoblastic leukemia ,Hematopoietic stem cell transplantation ,Haploidentical ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Survival analysis ,Transplantation ,Acute leukemia ,Acute myeloid leukemia ,business.industry ,Donor selection ,Hazard ratio ,Myeloid leukemia ,Hematology ,medicine.disease ,3. Good health ,030220 oncology & carcinogenesis ,business ,Settore MED/15 - Malattie del Sangue ,030215 immunology - Abstract
Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or matched unrelated donors are unavailable. As several potential haploidentical relative donors are typically available for a given patient, optimizing donor selection to improve clinical outcome is crucial. The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly established in this setting. Using the multinational registry of the acute leukemia working party of the European society for blood and marrow transplantation we retrospective analyzed the clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who underwent haplo-HCT between 2005 and 2015. Patients over the age of 40 were significantly affected by increasing donor age resulting in higher non-relapse mortality (NRM) [Hazard ratio (HR)=1.86, confidence interval (CI) 95%, 1.18-2.94; P = .007], inferior leukemia-free survival (LFS) (HR = 1.59, CI 95%, 1.13-2.24; P = .007), and overall survival (OS) (HR = 1.74, CI 95%, 1.22-2.47; P = .002) when donors were over the age of 40. Additionally, kinship was found to be prognostically significant as patients transplanted from children donors over the age of 35 experienced an increased rate of NRM (HR = 1.82, CI 95%, 1.13-2.9; P = .01), inferior LFS (HR = 1.5, CI 95%, 1.05-2.13; P = .03), and OS (HR = 1.5, CI 95%, 1.04-2.15; P = .03). For patients younger than 40 years, donor age and kinship were mostly not clinically impactful. Our data establish donor age and kinship as significant determinants of outcome following haplo-HCT for acute leukemia patients.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.